Deal News

  • 10 September 2019

    Flexion Therapeutics licences pain therapy from Xenon

    US-based Flexion Therapeutics has signed an agreement with Canadian Xenon Pharmaceuticals to acquire worldwide rights for the development and commercialisation of a NaV1.7 inhibitor, XEN402, to treat post-operative pain.

  • 6 September 2019

    IFM Due signs immunotherapy deal with Novartis

    IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis for the development of immunotherapies to address severe inflammatory and autoimmune disorders.

  • 6 September 2019

    Sumitomo Dainippon and Roivant form $3bn alliance

    Japan-based Sumitomo Dainippon Pharma has signed a memorandum of understanding (MoU) with healthcare technology company Roivant Sciences in a bid to provide new medicines to patients.

  • 5 September 2019

    BMS partners with BioMotiv to form new companies

    Biopharmaceutical company Bristol-Myers Squibb (BMS) has partnered with drug development accelerator BioMotiv to form and fund new companies for the advancement of medicines.

Close
Close
Close